Literature DB >> 20862625

[Treatment of pulmonary arterial hypertension (PAH): recommendations of the Cologne Consensus Conference 2010].

H A Ghofrani1, O Distler, F Gerhardt, M Gorenflo, E Grünig, W E Haefeli, M Held, M M Hoeper, C-M Kähler, H Kaemmerer, H Klose, V Köllner, B Kopp, S Mebus, A Meyer, O Miera, D Pittrow, G Riemekasten, S Rosenkranz, D Schranz, R Voswinckel, H Olschewski.   

Abstract

The 2009 European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension have been adopted for Germany. The guidelines contain detailed recommendations for the treatment of pulmonary arterial hypertension (PAH). However, the practical implementation of the European Guidelines in Germany requires the consideration of several country-specific issues and already existing novel data. This requires a detailed commentary to the guidelines, and in some aspects an update already appears necessary. In June 2010, a Consensus Conference organized by the PH working groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Pediatric Cardiology (DGPK) was held in Cologne, Germany. This conference aimed to solve practical and controversial issues surrounding the implementation of the European Guidelines in Germany. To this end, a number of working groups was initiated, one of which was specifically dedicated to the treatment of PAH. This commentary summarizes the results and recommendations of the working group on treatment of PAH. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20862625     DOI: 10.1055/s-0030-1263316

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  4 in total

Review 1.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

2.  [Pulmonary hypertension: Possible genetic causes and therapeutic options].

Authors:  E Grünig; C A Eichstaedt; N Ehlken; E Mayer; H Klose
Journal:  Herz       Date:  2015-05       Impact factor: 1.443

3.  [Pulmonary arterial hypertension].

Authors:  F Reichenberger; R Voswinckel
Journal:  Internist (Berl)       Date:  2011-04       Impact factor: 0.743

Review 4.  Regulation and interactions in the activation of cell-associated plasminogen.

Authors:  H Myöhänen; A Vaheri
Journal:  Cell Mol Life Sci       Date:  2004-11       Impact factor: 9.261

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.